Bradley J. Monk, MD, FACS, FACOG

Bradley J. Monk, MD, FACS, FACOG , joined the Florida Cancer Specialists & Research Institute in 2024 as medical director of the Late-Phase Clinical Research Program across the state network and is accountable for all cancer types. In addition, he is vice president of the GOG Foundation, for which he also serves on the board of directors, and director of the GOG Partners research consortium, which he cofounded in 2010.

Dr Monk graduated at the top of his class from The University of Arizona College of Medicine – Tucson in 1988 and completed a residency in obstetrics and gynecology at the University of California, Los Angeles in 1992. In 1995, he completed his fellowships in gynecologic oncology at the University of California, Irvine.

In 1995, Dr Monk became director of gynecologic oncology at Texas Tech University Health Services Center. From 1998 to 2010, he served as associate professor with tenure in the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, and director of research for the Department of Obstetrics and Gynecology at the University of California, Irvine Chao Family Comprehensive Cancer Center. In 2010, Dr Monk was appointed director and professor in the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center in Phoenix, AZ. He also became a professor on the clinical scholar track at The University of Arizona College of Medicine – Phoenix. In 2016, he transitioned to Arizona Oncology, part of the US Oncology Network. He served as chair of the Gynecologic Cancer Committee for US Oncology Research until 2022, when his practice was acquired by HonorHealth. He began serving as director and principal investigator at the Virginia G. Piper Cancer Center at HonorHealth, where he was also the site research leader for Sarah Cannon Research Institute.

Dr Monk’s research interests include the prevention and treatment of gynecologic cancers, and he has authored more than 450 peer-reviewed articles, along with more than 35 book chapters, focusing predominantly on these topics and on patient-reported outcomes. He was the first to report the activity of anti-VEGF therapy in ovarian and cervical cancers, and his papers in The New England Journal of Medicine led to the global approval of anti-VEGF therapy in recurrent cervical cancer in 2014 and advanced ovarian cancer in 2018. He was also the lead author of the pivotal trial of trabectedin in recurrent ovarian cancer, as well as many other studies that have met their primary end points. Additionally, his other papers in The New England Journal of Medicine, the Journal of Clinical Oncology, the Annals of Oncology, and The Lancet Oncology have led to multiple US Food and Drug Administration/European Medicines Agency approvals of PARP inhibitors, cytotoxic agents, and immunotherapy for advanced and recurrent ovarian, cervical, and endometrial cancers.

He serves on the editorial boards of multiple peer-reviewed oncology journals and is the gynecologic cancer section coeditor for the Annals of Oncology (the official journal of the European Society for Medical Oncology). Dr Monk is a fellow of the American College of Surgeons, the American College of Obstetricians and Gynecologists (board certified), and the American Society for Colposcopy and Cervical Pathology. He is also an active member of the Society of Gynecologic Oncology, the International Gynecologic Cancer Society, and the American Society of Clinical Oncology.

Dr Monk was awarded the highly prestigious Ernst Wertheim Award for his research in cervical cancer in Salzburg, Austria. He was chair of the Cervical Cancer Subcommittee for NRG Oncology for 11 years and is prior chair of the Cervical Cancer Committee for the Gynecologic Cancer Intergroup.